Meta Platforms has added another 1.5% this week to close at $578.54 — a quiet grind higher that extends the recovery from the August trough but leaves the stock still trading at a 23% discount to the Street's mean target of $754.77.
The most interesting tension right now is on the analyst side. The direction of recent coverage is unmistakably bullish in rating but increasingly bifurcated on target. Evercore ISI raised its target to $860 last week — one of the more aggressive calls on the Street — while Rosenblatt nudged its own Buy-rated target to $886. Yet on the same days, Truist Securities trimmed to $763 from $770, and Goldman Sachs cut to $725 from $815 after last month's earnings disappointment. Wedbush sat the fence, reiterating a Neutral with a $595 target that sits nearly $160 below the consensus. The message from the Street is that bulls remain in the majority but are not aligned on how much of the legal and regulatory drag to price in. A $595 Neutral and an $886 Buy on the same stock in the same week is about as wide a spread as you'll see on a mega-cap.
The bear case centres on the legal overhang. A potential $5.3 billion settlement with state attorneys general over child safety practices is the headline liability, but unresolved private litigation and ongoing costs related to the social media addiction trial keep the tail risk alive. The bull case leans on the obvious: is the largest social media company in the world, the core advertising engine is resilient, and forward earnings estimates remain robust — the eps_12m_fwd_yoy_increase factor ranks in the 85th percentile. The factor picture is mixed elsewhere. The dividend score sits at the 96th percentile, and the short-score rank at 82nd, reflecting the absence of meaningful short pressure. EPS momentum over both 30 and 90 days trails, ranking in the 35th percentile, which suggests estimate revisions have been drifting lower even as the long-term growth case holds.
Positioning tells a near-frictionless story on the short side — and that remains unchanged from last week's note. Short interest has dropped another 10.9% on the week to 1.3% of the free float. Over the past month it has fallen by more than a quarter. Borrow availability is essentially unlimited, with over 2.1 billion shares available to lend. Cost to borrow is just 0.35%. There is no short squeeze dynamic, no crowded positioning, and no sign that bearish traders are building new exposure into the legal headlines. Options are similarly quiet: the put/call ratio at 0.448 is nearly identical to its 20-day average of 0.448, with a z-score effectively at zero. The 52-week PCR high is 0.749 — today's reading is near the low end of the range. Defensiveness is not what options traders are expressing.
FMR LLC's 13G/A filed on August 6 disclosed a cut from 6.1% to 4.4% of shares — a notable reduction that takes Fidelity below the 5% threshold. Per standard 13D/G disclosure conventions, they may not file again if the stake falls further. On the other side, Capital Research added roughly 9.4 million shares in the most recent reporting period, and BlackRock added 4.6 million. Mark Zuckerberg's 591,690-share reduction in July was executed under a pre-arranged 10b5-1 plan, as have all recent insider sales across the register — these are scheduled disposals, not discretionary exits.
The earnings date on October 28 is the next hard catalyst. Last quarter META fell 9.2% the day after results, and the prior print saw a 5.9% drop. Both moves faded within five days, with the five-day return nearly flat in both cases. The next print will be a test of whether the legal settlement costs are being absorbed into guidance, and whether the advertising business can sustain the forward earnings trajectory the bulls are counting on.
See the live data behind this article on ORTEX.
Open META on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
